Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus.

Bodewes R, Kreijtz JH, Baas C, Geelhoed-Mieras MM, de Mutsert G, van Amerongen G, van den Brand JM, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

PLoS One. 2009;4(5):e5538. doi: 10.1371/journal.pone.0005538. Epub 2009 May 14.

2.

Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice.

Bodewes R, Kreijtz JH, Hillaire ML, Geelhoed-Mieras MM, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

J Gen Virol. 2010 Jul;91(Pt 7):1743-53. doi: 10.1099/vir.0.020784-0. Epub 2010 Mar 24.

PMID:
20335492
3.

Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets.

Bodewes R, Kreijtz JH, Geelhoed-Mieras MM, van Amerongen G, Verburgh RJ, van Trierum SE, Kuiken T, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

J Virol. 2011 Mar;85(6):2695-702. doi: 10.1128/JVI.02371-10. Epub 2011 Jan 12.

4.

Annual influenza vaccination affects the development of heterosubtypic immunity.

Bodewes R, Fraaij PL, Kreijtz JH, Geelhoed-Mieras MM, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

Vaccine. 2012 Dec 7;30(51):7407-10. doi: 10.1016/j.vaccine.2012.04.086. Epub 2012 May 27.

PMID:
22643217
5.

Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus.

Kreijtz JH, Bodewes R, van den Brand JM, de Mutsert G, Baas C, van Amerongen G, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

Vaccine. 2009 Aug 6;27(36):4983-9. doi: 10.1016/j.vaccine.2009.05.079. Epub 2009 Jun 16.

PMID:
19538996
7.

A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets.

Bodewes R, Kreijtz JH, van Amerongen G, Geelhoed-Mieras MM, Verburgh RJ, Heldens JG, Bedwell J, van den Brand JM, Kuiken T, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

J Virol. 2010 Aug;84(16):7943-52. doi: 10.1128/JVI.00549-10. Epub 2010 Jun 2.

8.

Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration.

Budimir N, de Haan A, Meijerhof T, Gostick E, Price DA, Huckriede A, Wilschut J.

Influenza Other Respir Viruses. 2013 Nov;7(6):1202-9. doi: 10.1111/irv.12142. Epub 2013 Sep 16.

9.

Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models.

Park SJ, Kim EH, Pascua PN, Kwon HI, Lim GJ, Decano A, Kim SM, Song MK, Shin EC, Choi YK.

J Gen Virol. 2014 Apr;95(Pt 4):793-8. doi: 10.1099/vir.0.058636-0. Epub 2014 Jan 13.

PMID:
24421115
10.

[Tetravaccine--new fundamental approach to prevention of influenza pandemic].

Onishchenko GG, Zverev VV, Katlinskiĭ AV, Semchenko AV, Korovkin SA, Mel'nikov SIa, Mironov AN.

Zh Mikrobiol Epidemiol Immunobiol. 2007 Jul-Aug;(4):15-9. Review. Russian.

PMID:
17882832
11.

Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza A viruses.

Furuya Y, Chan J, Regner M, Lobigs M, Koskinen A, Kok T, Manavis J, Li P, Müllbacher A, Alsharifi M.

J Virol. 2010 May;84(9):4212-21. doi: 10.1128/JVI.02508-09. Epub 2010 Feb 17.

12.

Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus.

Ding H, Tsai C, Zhou F, Buchy P, Deubel V, Zhou P.

PLoS One. 2011 Mar 25;6(3):e17821. doi: 10.1371/journal.pone.0017821.

13.

Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin.

Sawai T, Itoh Y, Ozaki H, Isoda N, Okamoto K, Kashima Y, Kawaoka Y, Takeuchi Y, Kida H, Ogasawara K.

Immunology. 2008 Jun;124(2):155-65. doi: 10.1111/j.1365-2567.2007.02745.x. Epub 2008 Jan 16.

14.

Yearly influenza vaccinations: a double-edged sword?

Bodewes R, Kreijtz JH, Rimmelzwaan GF.

Lancet Infect Dis. 2009 Dec;9(12):784-8. doi: 10.1016/S1473-3099(09)70263-4. Epub 2009 Oct 30.

PMID:
19879807
15.

Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.

Kreijtz JH, Bodewes R, van Amerongen G, Kuiken T, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

Vaccine. 2007 Jan 8;25(4):612-20. Epub 2006 Sep 7.

PMID:
17005299
16.

Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats.

Straight TM, Ottolini MG, Prince GA, Eichelberger MC.

Virol J. 2008 Mar 20;5:44. doi: 10.1186/1743-422X-5-44.

17.

Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain.

Droebner K, Haasbach E, Fuchs C, Weinzierl AO, Stevanovic S, Büttner M, Planz O.

Vaccine. 2008 Dec 9;26(52):6965-74. doi: 10.1016/j.vaccine.2008.09.051. Epub 2008 Oct 9.

PMID:
18848593
18.

A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.

Itoh Y, Ozaki H, Tsuchiya H, Okamoto K, Torii R, Sakoda Y, Kawaoka Y, Ogasawara K, Kida H.

Vaccine. 2008 Jan 24;26(4):562-72. doi: 10.1016/j.vaccine.2007.11.031. Epub 2007 Dec 3.

PMID:
18164788
19.

Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.

Park KS, Lee J, Ahn SS, Byun YH, Seong BL, Baek YH, Song MS, Choi YK, Na YJ, Hwang I, Sung YC, Lee CG.

Virology. 2009 Dec 20;395(2):182-9. doi: 10.1016/j.virol.2009.09.018.

20.

An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.

Zhao G, Sun S, Du L, Xiao W, Ru Z, Kou Z, Guo Y, Yu H, Jiang S, Lone Y, Zheng BJ, Zhou Y.

Virol J. 2010 Jul 12;7:151. doi: 10.1186/1743-422X-7-151.

Supplemental Content

Support Center